Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery

Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery

Lupin receives approval from USFDA for Pitavastatin Tablets

Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use

Zydus announces IND clearance of a novel Anti-PCSK9 candidate

Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity

Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData

This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

Israeli researchers develop an effective drug to prevent muscle diseases

The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.

Evonik opens new facility for pharmaceutical lipids in Germany

New GMP facility for clinical and small-scale commercial pharmaceutical lipids

Zydus receives final approval from the USFDA for Pitavastatin Tablets

IOL Chemicals and Pharmaceuticals Q3 FY23 income down 6%

The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins